恩华药业子公司召回重酒石酸卡巴拉汀胶囊

Core Viewpoint - The National Medical Products Administration (NMPA) has suspended the import, sale, and use of the Cabergoline capsules produced by Sun Pharmaceutical Industries Limited due to quality management deficiencies and non-compliance with China's drug production quality management standards [1][2]. Group 1: Company Response - Enhua Pharmaceutical's wholly-owned subsidiary, Jiangsu Enhua Hexin Pharmaceutical Marketing Co., Ltd., is responsible for the sales of the affected Cabergoline capsules in China and has initiated a three-level recall to ensure medication safety [1]. - The company anticipates that the sales revenue from the recalled product for the fiscal year 2025 will be approximately 40 million yuan, accounting for less than 1% of its total revenue [2]. - The estimated sales amount involved in the recall is around 9 million yuan, and the actual quantity and value of the recalled products are currently undetermined [2]. Group 2: Financial Impact - The company expects that the financial impact of the recall will be minimal, as the recalled product's sales amount represents a small proportion of the company's total revenue for the same period [2]. - The company reserves the right to take legal measures to address economic losses resulting from supplier issues, including inventory write-offs and product recalls [2].